PMID- 35087408
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220129
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Epigenetics and Beyond: Targeting Histone Methylation to Treat Type 2 Diabetes 
      Mellitus.
PG  - 807413
LID - 10.3389/fphar.2021.807413 [doi]
LID - 807413
AB  - Diabetes mellitus is a global public health challenge with high morbidity. Type 2 
      diabetes mellitus (T2DM) accounts for 90% of the global prevalence of diabetes. 
      T2DM is featured by a combination of defective insulin secretion by pancreatic 
      beta-cells and the inability of insulin-sensitive tissues to respond appropriately 
      to insulin. However, the pathogenesis of this disease is complicated by genetic 
      and environmental factors, which needs further study. Numerous studies have 
      demonstrated an epigenetic influence on the course of this disease via altering 
      the expression of downstream diabetes-related proteins. Further studies in the 
      field of epigenetics can help to elucidate the mechanisms and identify 
      appropriate treatments. Histone methylation is defined as a common histone mark 
      by adding a methyl group (-CH3) onto a lysine or arginine residue, which can 
      alter the expression of downstream proteins and affect cellular processes. Thus, 
      in tthis study will discuss types and functions of histone methylation and its 
      role in T2DM wilsed. We will review the involvement of histone methyltransferases 
      and histone demethylases in the progression of T2DM and analyze epigenetic-based 
      therapies. We will also discuss the potential application of histone methylation 
      modification as targets for the treatment of T2DM.
CI  - Copyright (c) 2022 Yang, Luan, Feng, Chen, Qin, Ren and Luan.
FAU - Yang, Yang
AU  - Yang Y
AD  - Department of Translational Medicine Center, the First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
FAU - Luan, Ying
AU  - Luan Y
AD  - Department of Physiology and Neurobiology, School of Basic Medical Sciences, 
      Zhengzhou University, Zhengzhou, China.
FAU - Feng, Qi
AU  - Feng Q
AD  - Research Institute of Nephrology, Zhengzhou University, Zhengzhou, China.
FAU - Chen, Xing
AU  - Chen X
AD  - Department of Translational Medicine Center, the First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
FAU - Qin, Bo
AU  - Qin B
AD  - Department of Translational Medicine Center, the First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
FAU - Ren, Kai-Di
AU  - Ren KD
AD  - Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, 
      Zhengzhou, China.
FAU - Luan, Yi
AU  - Luan Y
AD  - Department of Translational Medicine Center, the First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220111
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8788853
OTO - NOTNLM
OT  - epigenetic-based therapies
OT  - histone demethylases
OT  - histone methylation
OT  - histone methyltransferases
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/29 06:00
MHDA- 2022/01/29 06:01
PMCR- 2022/01/11
CRDT- 2022/01/28 05:53
PHST- 2021/11/02 00:00 [received]
PHST- 2021/12/24 00:00 [accepted]
PHST- 2022/01/28 05:53 [entrez]
PHST- 2022/01/29 06:00 [pubmed]
PHST- 2022/01/29 06:01 [medline]
PHST- 2022/01/11 00:00 [pmc-release]
AID - 807413 [pii]
AID - 10.3389/fphar.2021.807413 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Jan 11;12:807413. doi: 10.3389/fphar.2021.807413. 
      eCollection 2021.